Jump to content

Gordon Dougan

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 14:33, 25 March 2020 (Add: pmid, bibcode. Removed URL that duplicated unique identifier. | You can use this bot yourself. Report bugs here. | Activated by User:Josve05a | via #UCB_toolbar). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Gordon Dougan
Alma materUniversity of Sussex
AwardsFRS (2012)

FMedSci

EMBO member (2011)
Scientific career
Institutions
ThesisAn Analysis of the Structure and Function of Plasmid ColE1 (1977)
Websitecitiid.cam.ac.uk/gordon-dougan/

Professor Gordon Dougan is a world authority on vaccines, genomics and the epidemiology of infectious diseases including antibiotic resistance.[1][2][3] He has contributed to the development of several vaccines (e.g. whooping cough, cholera, typhoid) and was previously voted in the top ten most influential people in the vaccine world.[4] He has served on numerous international bodies and organisations including, the World Health Organization,[5] the GSK Institute for Global Health,[6] the International Vaccine Institute (Korea) [7] and Wellcome.[8] He is currently a Professor in the Department of Medicine, University of Cambridge [9] and was formerly Head of Pathogen Research at the Wellcome Sanger Institute.[10] He has worked in the Pharmaceutical industry developing vaccine for over a decade.

Education

Gordon was educated in his home town of Scunthorpe in England and received his BSc and PhD from the University of Sussex, where he studied antibiotic resistance.[11] He completed his postdoctoral research at the University of Washington (Seattle) in the laboratory of Professor Stanley Falkow. He holds Masters Degrees from Trinity College Dublin[12] and Wolfson College, University of Cambridge.[13] He is a visiting professor at the London School for Hygiene and Tropical Medicine[14] and an adjunct professor at Monash[15] and Melbourne[16] universities in Australia.

Research and career

After graduating from Sussex University with a PhD, he trained with Professor Stanley Falkow at the University of Washington in Seattle, a Lasker Prize winner and world leader in studies on how bacteria cause disease. After a short spell lecturing at Trinity College, Dublin.[17] Gordon then spent over 10 years in industry at The Wellcome Foundation (a UK company now part of GSK) working on vaccines and other medicines. There his group helped define the protective antigen pertactin,[1] now part of acellular whooping cough vaccines.

Gordon left industry in 1992 and moved to Imperial College London,[18] where he established The Centre for Molecular Microbiology and Infection (now MRC Centre for Molecular Bacteriology and Infection)[19] and secured the funding for a new building (The Flowers Building) adjacent to the British Science Museum. He spent 10 years at Imperial, building a world leading centre for teaching and research and discovered key mucosal adjuvants.[20]

In 2004, he became Head of Pathogen Research at the Wellcome Sanger Institute in Cambridge, a world leading centre for genomic research. Over the next decade he built a department that led the world in research on pathogen genomics and disease tracking. His article on cholera genomics, published in the journal Nature,[21] redefined our understanding of how the disease spreads around the world. His team also highlighted the key role of antibiotic resistance in shaping pathogen evolution, tracking epidemic clades such as H58 in typhoid [22] and ST313 in invasive non-typhoidal salmonellosis[23] in Africa. His teams also contributed to the discovery of the role of the gene IFITM3 in controlling influenza susceptibility.[24]

Gordon has worked extensively with WHO. He chaired the Novartis Vaccine SAB for many years. He served on the Board of Directors of the Hilleman Laboratories[25] where he helped bring in the stabilised oral cholera (Hikojima/Hillcol) vaccine now being developed in India. Gordon has founded companies including Microbiotica[26] working on novel approaches to tackling infections via bacteriotherapies.

Gordon is currently a Professor in the Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge and an advisor to Wellcome.

Awards and honours

Gordon was elected a Fellow of the Academy of Medical Sciences in 2001, a member of the European Molecular Biology Organization (EMBO) in 2011, a Fellow of The American Society for Microbiology in 2010, and a Fellow of The Royal Society in 2012. He is the only person to have won the Fleming Lectureship, The Colworth Lectureship and the Marjory Stephenson Lectureship prizes awarded by the Microbiology Society.

Personal life

He has been a lifelong supporter of Scunthorpe United and is an experienced beekeeper.

References

  1. ^ a b Charles, I. G.; Dougan, G.; Pickard, D.; Chatfield, S.; Smith, M.; Novotny, P.; Morrissey, P.; Fairweather, N. F. (1 May 1989). "Molecular cloning and characterization of protective outer membrane protein P.69 from Bordetella pertussis". Proceedings of the National Academy of Sciences. 86 (10): 3554–3558. Bibcode:1989PNAS...86.3554C. doi:10.1073/pnas.86.10.3554. ISSN 0027-8424. PMC 287176. PMID 2542937.
  2. ^ Mutreja, Ankur; Kim, Dong Wook; Thomson, Nicholas R.; Connor, Thomas R.; Lee, Je Hee; Kariuki, Samuel; Croucher, Nicholas J.; Choi, Seon Young; Harris, Simon R.; Lebens, Michael; Niyogi, Swapan Kumar (24 August 2011). "Evidence for several waves of global transmission in the seventh cholera pandemic". Nature. 477 (7365): 462–465. Bibcode:2011Natur.477..462M. doi:10.1038/nature10392. ISSN 1476-4687. PMC 3736323. PMID 21866102.
  3. ^ Klemm, Elizabeth J.; Wong, Vanessa K.; Dougan, Gordon (18 December 2018). "Emergence of dominant multidrug-resistant bacterial clades: Lessons from history and whole-genome sequencing". Proceedings of the National Academy of Sciences of the United States of America. 115 (51): 12872–12877. doi:10.1073/pnas.1717162115. ISSN 1091-6490. PMC 6304985. PMID 30559200.
  4. ^ "Plotkin and Offit in Top Ten Most Influential in Vaccines | History of Vaccines". www.historyofvaccines.org. Retrieved 20 March 2020.
  5. ^ "Home". www.who.int. Retrieved 20 March 2020.
  6. ^ Breuer, Thomas; Officer, Chief Medical; Vaccines, G. S. K. "Inside the GVGH | GSK". admin-awsproduction.gsk.com. Retrieved 20 March 2020.
  7. ^ "IVI - International Vaccine Institute". Retrieved 20 March 2020.
  8. ^ "Home | Wellcome". wellcome.ac.uk. Retrieved 20 March 2020.
  9. ^ "CITIID". Cambridge Institute of Therapeutic Immunology & Infectious Disease. Retrieved 20 March 2020.
  10. ^ www-core (webteam). "Home Page". www.sanger.ac.uk. Retrieved 20 March 2020.
  11. ^ Dougan, Gordon; Sherratt, David (January 1977). "The transposon Tn1 as a probe for studying ColE1 structure and function". Molecular and General Genetics MGG. 151 (2): 151–160. doi:10.1007/BF00338689. ISSN 0026-8925. PMID 327263.
  12. ^ "Trinity College Dublin, the University of Dublin, Ireland". www.tcd.ie. Retrieved 20 March 2020.
  13. ^ "Wolfson College Cambridge: Homepage". www.wolfson.cam.ac.uk. Retrieved 20 March 2020.
  14. ^ "The London School of Hygiene & Tropical Medicine". LSHTM. Retrieved 20 March 2020.
  15. ^ "Monash University". Monash University. Retrieved 20 March 2020.
  16. ^ Harris, Andrew (7 January 2019). "The University of Melbourne, Australia - Australia's best university and one of the world's finest". The University of Melbourne. Retrieved 20 March 2020.
  17. ^ Kehoe, Michael; Sellwood, Richard; Shipley, Patricia; Dougan, Gordon (May 1981). "Genetic analysis of K88-mediated adhesion of enterotoxigenic Escherichia coli". Nature. 291 (5811): 122–126. Bibcode:1981Natur.291..122K. doi:10.1038/291122a0. ISSN 0028-0836. PMID 7015144.
  18. ^ "Imperial College London". Imperial College London. Retrieved 20 March 2020.
  19. ^ "MRC Centre for Molecular Bacteriology and Infection". Imperial College London. Retrieved 20 March 2020.
  20. ^ Douce, G.; Turcotte, C.; Cropley, I.; Roberts, M.; Pizza, M.; Domenghini, M.; Rappuoli, R.; Dougan, G. (28 February 1995). "Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants". Proceedings of the National Academy of Sciences. 92 (5): 1644–1648. Bibcode:1995PNAS...92.1644D. doi:10.1073/pnas.92.5.1644. ISSN 0027-8424. PMC 42576. PMID 7878032.
  21. ^ Mutreja, Ankur; Kim, Dong Wook; Thomson, Nicholas R.; Connor, Thomas R.; Lee, Je Hee; Kariuki, Samuel; Croucher, Nicholas J.; Choi, Seon Young; Harris, Simon R.; Lebens, Michael; Niyogi, Swapan Kumar (September 2011). "Evidence for several waves of global transmission in the seventh cholera pandemic". Nature. 477 (7365): 462–465. Bibcode:2011Natur.477..462M. doi:10.1038/nature10392. ISSN 0028-0836. PMC 3736323. PMID 21866102.
  22. ^ Wong, Vanessa K; Baker, Stephen; Pickard, Derek J; Parkhill, Julian; Page, Andrew J; Feasey, Nicholas A; Kingsley, Robert A; Thomson, Nicholas R; Keane, Jacqueline A; Weill, François-Xavier; Edwards, David J (June 2015). "Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events". Nature Genetics. 47 (6): 632–639. doi:10.1038/ng.3281. ISSN 1061-4036. PMC 4921243. PMID 25961941.
  23. ^ Okoro, Chinyere K; Kingsley, Robert A; Connor, Thomas R; Harris, Simon R; Parry, Christopher M; Al-Mashhadani, Manar N; Kariuki, Samuel; Msefula, Chisomo L; Gordon, Melita A; de Pinna, Elizabeth; Wain, John (November 2012). "Intracontinental spread of human invasive Salmonella Typhimurium pathovariants in sub-Saharan Africa". Nature Genetics. 44 (11): 1215–1221. doi:10.1038/ng.2423. ISSN 1061-4036. PMC 3491877. PMID 23023330.
  24. ^ Everitt, Aaron R.; Clare, Simon; Pertel, Thomas; John, Sinu P.; Wash, Rachael S.; Smith, Sarah E.; Chin, Christopher R.; Feeley, Eric M.; Sims, Jennifer S.; Adams, David J.; Wise, Helen M. (25 March 2012). "IFITM3 restricts the morbidity and mortality associated with influenza". Nature. 484 (7395): 519–523. Bibcode:2012Natur.484..519.. doi:10.1038/nature10921. ISSN 0028-0836. PMC 3648786. PMID 22446628.
  25. ^ "Hilleman Laboratories- Vaccine Research and Development Organization with High Impact Vaccines in Delhi, India". www.hillemanlabs.org. Retrieved 22 March 2020.
  26. ^ "Microbiotica - Home". www.microbiotica.com. Retrieved 20 March 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Gordon_Dougan&oldid=947302689"